Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07481604
PHASE2

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

Sponsor: CHA Vaccine Institute Co., Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.

Official title: A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

135

Start Date

2026-04

Completion Date

2027-01

Last Updated

2026-03-19

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

Shingrix

Licensed herpes zoster vaccine used as an active comparator.

BIOLOGICAL

CVI-VZV-001

Investigational herpes zoster vaccine.

Locations (7)

Kyungpook National University Chilgok Hospital

Daegu, Daegu, South Korea

CHA Bundang Medical Center

Seongnam-si, Gyeonggi-do, South Korea

Yongin Severance Hospital, Yonsei University Health System

Yongin, Gyeonggi-do, South Korea

Jeonbuk National University Hospital

Jeonju, Jeollabuk-do, South Korea

The Catholic University of Korea Eunpyeong St. Mary's Hospital

Seoul, Seoul, South Korea

Chung-Ang University Hospital

Seoul, Seoul, South Korea

Ewha Womans University Seoul Hospital

Seoul, Seoul, South Korea